MedTrace Logo

ALPPS: Safety, Feasibility and Efficacy at a Single Center

NCT02164292 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-08-13

No results posted yet for this study

Summary

The possibility to achieve a curative resection in patients with liver malignancies is limited by the future liver remnant (FLR). The Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) approach has recently been introduced as a revolutionary strategy to achieve resectability by inducing a rapid and large FLR hypertrophy. However, the possibility of achieving a short-term hypertrophy and high resectability rates has been counteracted in most published series by an increased risk of morbidity and mortality.The aim of this study was to evaluate the results with the ALPPS procedure in a single high-volume HPB center, with special emphasis in the safety and feasibility of this new 2-stage strategy. The aim of the present study was to assess the safety, feasibility and efficacy of ALPPS in a single high-volume hepatobiliary center.

Conditions

  • Locally Advanced Malignant Liver Disease

Interventions

PROCEDURE

ALPPS

Associating Liver Partition and Portal vein ligation for Staged hepatectomy

Sponsors & Collaborators

  • Hospital Italiano de Buenos Aires

    lead OTHER

Principal Investigators

  • Eduardo de Santibañes, MD, PhD · General Surgery Service, Hospital Italiano de Buenos Aires. Argentina

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Argentina

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02164292 on ClinicalTrials.gov